virus
possess
class
fusion
protein
requir
proteolyt
activ
host
cell
proteas
mediat
fusion
host
cell
membran
mammalian
gene
encod
proteas
inhibitor
target
trypsinlik
serin
proteas
show
proteas
inhibitor
restrict
cleavageactiv
effici
rang
influenza
virus
human
metapneumoviru
hmpv
treatment
result
cleavag
fusion
inhibit
fulllength
influenza
ha
ha
ha
hmpv
f
activ
trypsin
recombin
matriptas
also
demonstr
abl
reduc
viral
growth
influenza
cell
cultur
inhibit
matriptas
moreov
inhibit
efficaci
differ
whether
ad
time
infect
h
postinfect
data
suggest
inhibitor
strong
potenti
serv
novel
broadspectrum
antivir
influenzalik
ill
ili
repres
signific
burden
public
health
caus
rang
respiratori
virus
addit
influenza
viru
world
health
organ
ongo
goal
antivir
drug
discoveri
develop
broadlyact
therapeut
use
absenc
definit
diagnosi
case
ili
strategi
succeed
drug
target
share
across
viru
famili
need
identifi
one
common
caus
influenza
shape
term
ili
influenza
virus
includ
cross
speci
barrier
natur
avian
host
infect
human
fouchier
guan
yen
webster
novel
emerg
virus
caus
hundr
death
sinc
appear
china
pose
addit
concern
world
health
organ
world
health
organ
estim
year
billion
suffer
flu
infect
million
peopl
worldwid
hospit
sever
ill
approxim
peopl
die
diseas
world
health
organ
mortal
rate
dramat
rise
influenza
pandem
observ
spanish
flu
asian
pandem
hong
kong
pandem
yen
webster
kilbourn
vaccin
provid
effect
protect
season
pandem
outbreak
provid
limit
protect
virus
evolv
andor
acquir
mutat
result
antigen
distinct
virus
antigen
drift
shift
requir
new
vaccin
produc
quickli
vast
amount
problemat
especi
pandem
addit
vaccin
sever
antivir
therapi
appli
treat
influenza
infect
adamantan
act
ion
channel
blocker
amantadin
rimantadin
neuraminidas
inhibitor
block
cleavag
sialic
acid
newli
form
virion
oseltamivir
zanamivir
hussain
et
al
howev
sever
influenza
subtyp
includ
common
emerg
global
resist
adamantan
similar
observ
made
respect
oseltamivir
hussain
et
al
recent
baloxavir
marboxil
bxm
inhibitor
influenza
polymeras
acid
subunit
pa
approv
antivir
therapi
takashita
et
al
although
fulli
effect
current
circul
influenza
b
virus
clinic
trial
studi
alreadi
shown
treatment
bxm
select
influenza
viru
specif
amino
acid
substitut
pa
result
reduc
suscept
drug
hayden
http
receiv
octob
receiv
revis
form
decemb
accept
januari
omoto
et
al
anoth
common
caus
ili
pneumoand
paramyxovirus
includ
human
metapneumoviru
hmpv
respiratori
syncyti
viru
parainfluenza
virus
clinic
present
virus
resembl
mani
symptom
influenza
caus
signific
morbid
mortal
well
larg
econom
burden
taylor
et
al
li
et
al
hmpv
ubiquit
nearli
everyon
infect
age
reinfect
common
throughout
life
impact
children
elderli
immunocompromis
individu
kahn
van
den
hoogen
et
al
leung
et
al
hmpv
common
caus
ili
current
approv
vaccin
antivir
therapeut
research
need
establish
target
intervent
factor
requir
infect
need
examin
detail
certain
influenza
virus
hmpv
appear
share
common
activ
proteas
influenza
fusion
protein
hemagglutinin
ha
synthes
precursor
need
cleav
host
cell
proteas
exert
fusogen
activ
steinhauer
taubenberg
cleavag
separ
precursor
ha
ha
ha
remain
associ
via
disulfid
bond
lead
exposur
fusion
peptid
nterminu
ha
steinhauer
taubenberg
low
pathogen
avian
influenza
lpai
usual
possess
monobas
cleavag
site
consist
nonconsecut
basic
amino
acid
gener
cleav
trypsinlik
serin
proteas
trypsin
well
member
type
ii
transmembran
serin
proteas
ttsp
famili
includ
hat
matriptas
steinhauer
taubenberg
et
al
addit
proteas
klk
implic
influenza
pathogen
hamilton
whittak
human
proteas
local
respiratori
tract
therefor
influenza
infect
usual
confin
tissu
contrast
highli
pathogen
avian
influenza
hpai
virus
defin
polybas
cleavag
site
consist
basic
residu
allow
activ
member
proprotein
convertas
pc
famili
furin
horimoto
et
al
proteas
confin
specif
tissu
dramat
increas
risk
system
infect
similar
influenza
ha
hmpv
requir
fusion
protein
f
proteolyt
process
singl
basic
residu
gener
activ
metast
form
without
cleavag
process
f
protein
unabl
mediat
viral
entri
target
cell
howev
date
trypsin
shown
effect
cleav
hmpv
f
proteas
yet
identifi
shirogan
et
al
schowalt
et
al
addit
respiratori
virus
report
util
similar
proteas
activ
includ
sarscov
merscov
demonstr
target
proteas
would
inhibit
multipl
respiratori
pathogen
millet
whittak
fact
proteolyt
activ
crucial
step
sever
respiratori
virus
predomin
requir
specif
class
proteas
make
proteas
viabl
target
develop
novel
antivir
therapi
laport
naesen
earlier
studi
describ
administr
serin
proteas
inhibitor
aprotinin
inhibit
influenza
replic
demonstr
aprotinin
success
inhibit
iav
activ
replic
zhirnov
et
al
howev
target
host
specif
factor
potenti
target
effect
therefor
potenti
side
effect
target
host
proteas
requir
investig
hamilton
et
al
report
hepatocyt
growth
activ
inhibitor
effect
inhibit
trypsinmedi
cleavag
vitro
vivo
hamilton
et
al
encod
gene
hereaft
also
refer
protein
kda
plasma
membraneloc
serin
proteas
inhibitor
found
epitheli
cell
variou
tissu
includ
respiratori
tract
major
organ
szabo
et
al
tissu
coloc
matriptas
suggest
regulatori
role
matriptasemedi
cleavag
event
howev
find
also
express
brain
lymph
node
cell
indic
might
regul
proteas
matriptas
szabo
et
al
recent
report
associ
physiolog
role
inhibit
human
serinetyp
proteas
matriptas
plasmin
kallikrein
klk
coagul
factor
xia
wu
et
al
wu
et
al
roversi
et
al
delaria
et
al
possess
one
transmembran
domain
two
kunitztyp
inhibitor
domain
expos
extracellular
space
believ
facilit
potent
inhibit
target
proteas
wu
et
al
recent
describ
kunitztyp
domain
respons
matriptas
inhibit
wu
et
al
major
function
role
tumor
suppressor
downregul
diminish
prospect
surviv
sever
cancer
hepatocellular
carcinoma
gastric
cancer
prostat
cancer
melanoma
fukai
et
al
dong
et
al
tsai
et
al
hwang
et
al
howev
also
associ
placenta
develop
epitheli
homeostasi
szabo
et
al
wu
et
al
previou
studi
lab
describ
effect
inhibit
trypsin
result
dramat
reduc
cleavag
influenza
ha
use
model
proteas
subsequ
reduc
viral
growth
cell
cultur
mous
studi
hamilton
et
al
report
purifi
protein
inhibit
sever
host
proteas
found
human
respiratori
tract
matriptas
relev
activ
influenza
virus
current
circul
caus
signific
diseas
outbreak
demonstr
broad
applic
also
test
potenti
inhibit
activ
fusion
protein
f
human
metapneumoviru
hmpv
member
pneumoviru
famili
confirm
origin
find
hmpv
f
proteolyt
process
trypsin
addit
found
hat
matriptas
abl
cleav
f
could
result
show
inhibit
activ
proteas
respons
activ
influenza
ha
well
hmpv
f
cell
cultur
model
demonstr
viral
load
significantli
reduc
presenc
infect
conduct
aca
moreov
applic
h
post
infect
inhibit
activ
influenza
virus
efficaci
ad
cell
cultur
medium
time
infect
thu
exhibit
potenti
serv
novel
effici
antivir
therapeut
reliev
patient
influenza
human
metapneumoviru
sarscov
potenti
respiratori
virus
requir
host
factor
entri
use
peptid
cleavag
assay
util
fluorogen
peptid
mimick
ha
cleavag
site
previous
test
abil
inhibit
proteas
shown
cleav
season
pandem
influenza
strain
infect
human
jaim
et
al
strau
whittak
found
certain
ha
subtyp
cleav
wide
varieti
human
respiratori
proteas
other
display
variabl
cleavag
proteas
seem
less
well
adapt
proteas
present
human
respiratori
tract
strau
whittak
extend
previou
studi
test
peptid
mimick
cleavag
site
pneumoviru
fusion
protein
hmpv
f
use
varieti
proteas
known
abil
cleav
peptid
mimic
tabl
schowalt
et
al
biacchesi
et
al
test
cleavag
peptid
mimick
hmpv
f
cleavag
site
use
trypsin
matriptas
hat
plasmin
found
proteas
except
abl
proteolyt
cleav
peptid
tabl
howev
vmax
valu
matriptas
rfu
min
rfumin
hat
rfumin
low
compar
trypsin
rfumin
suggest
three
proteas
low
affin
interact
process
hmpv
f
next
trypsin
matriptas
select
inhibit
assay
describ
inhibit
assay
trypsin
typic
resid
intestin
tract
express
broad
activ
toward
differ
ha
subtyp
hmpv
f
serv
control
galloway
et
al
addit
furin
use
neg
control
inhibit
none
peptid
use
combin
aforement
proteas
furin
cleavag
site
test
furinmedi
cleavag
peptid
hpai
cleavag
motif
presenc
nm
supplementari
fig
continu
measur
vmax
valu
proteasepeptid
combin
presenc
differ
concentr
plot
obtain
vmax
valu
concentr
logarithm
scale
supplementari
fig
use
softwar
determin
ic
reflect
concentr
v
max
respect
reaction
inhibit
half
cleavag
inhibit
repres
cleavag
site
trypsin
result
valu
nm
tabl
inhibit
efficaci
toward
matriptas
hat
rang
nm
nm
tabl
howev
inhibit
much
less
effici
plasmin
compar
trypsin
nm
observ
similar
trend
test
peptid
mimick
ha
cleavag
site
use
trypsin
hat
plasmin
trypsin
matriptas
plasmin
respect
tabl
except
plasmin
found
human
respiratori
tract
proteas
inhibit
higher
efficaci
compar
trypsin
expand
analysi
peptid
mimick
ha
cleavag
site
lpai
hpai
reflect
result
describ
tabl
cleavag
inhibit
ha
significantli
differ
observ
made
trypsin
tabl
test
inhibit
hmpv
cleavag
trypsin
matriptas
demonstr
high
inhibit
efficaci
three
test
proteas
measur
trypsin
matriptas
nm
nm
nm
respect
tabl
compar
valu
observ
peptid
mimick
influenza
ha
cleavag
site
motif
valu
hmpv
f
peptid
low
cleavag
peptid
mimick
cleavag
site
viral
fusion
protein
alway
reflect
vivo
situat
requir
valid
express
fulllength
fusion
protein
cell
cultur
model
test
cleavag
cleavag
inhibit
respect
proteas
strau
whittak
howev
conduct
experi
want
ensur
cytotox
effect
cell
therefor
cell
incub
variou
concentr
time
period
h
pb
h
serv
cytotox
neg
posit
control
respect
observ
slight
reduct
cell
viabil
ad
cell
fig
test
cleavag
inhibit
fulllength
ha
express
cell
ad
recombin
matriptas
proteas
preincub
nm
nm
trypsin
respect
proteas
without
incub
use
control
cleavag
ha
analyz
via
western
blot
signal
intens
ha
band
quantifi
use
control
sampl
without
incub
refer
point
illustr
rel
cleavag
ha
without
inhibitor
fig
bd
trypsin
cleav
test
ha
protein
high
effici
observ
matriptas
fig
howev
ha
cleav
matriptas
similar
extent
without
nm
nm
led
rel
cleavag
reduct
matriptas
respect
fig
b
cleavag
ha
reduc
preincub
nm
nm
use
fig
c
test
cleavag
inhibit
matriptas
ha
substrat
found
nm
nm
spint
reduc
cleavag
cleavag
respect
compar
control
fig
contrast
nm
effect
cleavag
ha
nm
reduc
rel
cleavag
approxim
fig
order
determin
whether
also
prevent
cleavag
hmpv
f
first
examin
proteas
addit
trypsin
abl
cleav
hmpv
f
first
cotransfect
full
length
hat
matriptas
hmpv
f
vero
cell
f
protein
radioact
label
methionin
cleavag
examin
quantifi
f
full
length
protein
f
cleavag
product
found
hat
abl
effici
cleav
hmpv
f
matriptas
decreas
express
f
though
clear
due
gener
degrad
protein
lower
initi
express
howev
matriptas
demonstr
potenti
lowlevel
cleavag
cotransfect
fig
b
examin
cleavag
exogen
proteas
matriptas
compar
trypsin
control
matriptas
abl
cleav
hmpv
f
fig
agreement
peptid
assay
cleavag
hmpv
f
matriptas
less
effici
trypsin
peptid
fulllength
protein
assay
demonstr
cleav
hmpv
f
also
serv
confirm
matriptas
like
cleav
hmpv
f
coexpress
matriptas
may
alter
protein
synthesi
stabil
turnov
coexpress
synthesi
transport
cell
surfac
next
test
inhibit
exogen
proteas
trypsin
matriptas
preincub
proteas
ad
vero
cell
express
hmpv
f
analyz
cleavag
product
format
preincub
minim
affect
cleavag
concentr
nm
addit
nm
result
inhibit
trypsin
matriptasemedi
cleavag
hmpv
similar
find
ha
fig
f
present
biochem
experi
demonstr
abl
effici
inhibit
proteolyt
cleavag
hmpv
f
sever
influenza
ha
subtyp
varieti
proteas
function
analysi
determin
whether
inhibit
prevent
cell
cell
fusion
viral
growth
examin
influenza
infect
cell
cultur
hmpv
import
human
pathogen
influenza
grow
significantli
better
cell
cultur
compar
hmpv
first
test
whether
cleavag
inhibit
result
inhibit
cellcel
fusion
describ
matriptas
preincub
nm
nm
subsequ
ad
vero
cell
express
ha
ha
cell
briefli
expos
low
ph
buffer
induc
fusion
subsequ
analyz
use
immun
fluoresc
assay
matriptas
test
nm
incub
vero
cell
express
ha
still
observ
syncytia
format
fig
howev
mm
result
abrog
syncytia
format
trigger
cleavag
respect
ha
matriptas
made
observ
test
ha
fig
matriptasemedi
ha
syncytia
format
inhibit
addit
nm
fig
ensur
cellcel
fusion
inhibit
result
ha
cleavag
inhibit
side
effect
treatment
per
se
express
ha
vero
cell
treat
inhibitor
ha
possess
hpai
cleavag
site
cleav
intracellularli
furin
matur
process
inhibit
furin
abl
cross
cell
membran
thu
interfer
proteolyt
process
ha
therefor
control
allow
examin
whether
interfer
cellcel
fusion
fig
show
ha
form
larg
syncytia
absenc
well
presenc
nm
henc
conclud
direct
inhibitori
effect
cellcel
fusion
understand
whether
abl
inhibit
reduc
growth
viru
cell
cultur
model
cours
h
cell
transfect
plasmid
encod
indic
ha
allow
express
protein
h
recombin
proteas
incub
min
indic
concentr
subsequ
ad
cell
min
trypsin
min
matriptas
western
blot
perform
ha
band
quantifi
use
imagej
quantif
band
compar
signal
intens
nm
sampl
nm
nm
respect
ha
proteas
combin
three
independ
experi
carri
western
blot
experi
analyz
quantif
conduct
describ
method
section
b
western
blot
show
cleavag
b
ha
matriptas
differ
concentr
c
ha
differ
concentr
ha
matriptas
differ
concentr
statist
analysi
perform
use
nonpair
student
ttest
compar
sampl
test
nm
respect
sampl
incub
nm
error
bar
indic
standard
deviat
indic
p
transfect
cell
human
human
matriptas
two
major
proteas
shown
respons
activ
distinct
influenza
subtyp
virus
essenti
viru
propag
mice
play
major
role
activ
virus
hatesu
et
al
sakai
et
al
baron
et
al
matriptas
cleav
ha
subtyp
specif
manner
involv
vivo
cleavag
ha
result
describ
suggest
role
matriptas
activ
hamilton
whittak
baron
et
al
h
post
transfect
infect
mdck
cell
moi
subsequ
ad
protein
differ
concentr
nontransfect
cell
serv
control
exogen
trypsin
ad
facilit
viral
propag
supernat
harvest
h
post
infect
viral
titer
subsequ
fig
hat
matriptas
cleav
hmpv
f
abl
prevent
cleavag
exogen
proteas
hmpv
f
either
express
alon
cotransfect
proteas
allow
express
h
cell
metabol
starv
cystein
methionin
follow
radioact
label
protein
h
presenc
tpcktrypsin
specifi
proteas
treat
proteas
incub
room
temperatur
min
place
onto
cell
h
radioact
gel
quantifi
use
imagequ
softwar
percent
cleavag
equal
b
cotransfect
proteas
hat
matriptas
abl
cleav
hmpv
f
n
c
exogen
proteas
matriptas
abl
cleav
hmpv
f
n
e
f
prevent
cleavag
hmpv
f
trypsin
matriptas
nm
concentr
demonstr
loss
f
cleavag
product
n
statist
analysi
perform
use
oneway
anova
follow
student
ttest
bonferroni
multipl
comparison
test
correct
p
p
p
p
n
valu
repres
independ
replic
treatment
group
error
bar
repres
sd
analyz
use
immunoplaqu
assay
initi
mitig
trypsinmedi
growth
concentr
nm
extent
inhibit
slightli
increas
higher
concentr
fig
tabl
highest
test
concentr
nm
reduc
viral
growth
log
fig
tabl
observ
similar
pattern
cell
transfect
human
matriptas
fig
tabl
growth
inhibit
start
concentr
nm
applic
nm
growth
reduc
approxim
log
fig
tabl
infect
cell
express
ad
viral
growth
significantli
reduc
concentr
nm
addit
nm
led
reduct
viral
growth
log
fig
tabl
also
test
whether
could
reduc
growth
viru
major
circul
season
influenza
subtyp
howev
matriptas
seem
activ
virus
hamilton
whittak
et
al
henc
trypsin
ad
growth
medium
cell
infect
compar
control
cell
without
ad
inhibitor
significantli
inhibit
trypsinmedi
growth
concentr
nm
fig
tabl
highest
concentr
nm
viral
growth
reduc
log
fig
also
examin
effect
inhibit
hmpv
spread
time
vero
cell
infect
rghmpv
moi
subsequ
treat
nm
tpcktrypsin
everi
h
cell
scrape
amount
viru
present
titer
trypsin
replenish
daili
found
untreat
cell
infect
demonstr
signific
spread
convers
cell
infect
treat
detect
viru
minim
viru
detect
demonstr
significantli
inhibit
hmpv
viral
replic
spread
fig
antivir
therapi
often
appli
patient
alreadi
show
sign
diseas
therefor
test
abl
reduc
viral
growth
ad
cell
h
initi
infect
cell
infect
moi
trypsin
ad
promot
viral
growth
time
infect
also
ad
nm
one
sampl
second
sampl
receiv
nm
h
post
infect
growth
supernat
harvest
h
later
viral
growth
analyz
found
viral
growth
significantli
reduc
regardless
whether
ad
time
infect
h
later
fig
tabl
influenza
viru
caus
four
pandem
sinc
earli
centuri
infect
million
peopl
year
season
flu
result
death
annual
world
health
organ
vaccin
effort
proven
challeng
due
antigen
drift
viru
emerg
resist
phenotyp
houser
subbarao
moreov
efficaci
vaccin
seem
significantli
reduc
certain
highrisk
group
karlsson
et
al
preval
antivir
therapi
treat
influenza
virusinfect
patient
adamantan
neuraminidas
inhibitor
target
viral
protein
increas
number
report
circul
influenza
subtyp
resist
treatment
hussain
et
al
hmpv
caus
infect
upper
lower
respiratori
tract
express
similar
symptom
influenza
infect
result
signific
morbid
mortal
taylor
et
al
li
et
al
suscept
group
young
children
older
adult
peopl
immunocompromis
kahn
van
den
hoogen
et
al
leung
et
al
current
treatment
hmpv
infect
avail
studi
focus
novel
approach
use
antivir
therapi
target
host
factor
rather
viral
protein
offer
broad
potenti
effect
therapeut
approach
laport
naesen
demonstr
potent
inhibitor
serinetyp
proteas
abl
significantli
inhibit
cleavag
hmpv
f
ha
impair
hatrigg
fusion
cell
henc
reduc
growth
variou
influenza
strain
cell
cultur
assess
cleavag
hmpv
fusion
protein
vitro
use
peptid
cleavag
assay
modifi
previous
work
viral
fusion
protein
jaim
et
al
strau
whittak
hmpv
f
peptid
cleav
trypsin
plasmin
matriptas
unabl
cleav
confirm
find
system
entir
hmpv
f
protein
subject
cleavag
coexpress
fusion
protein
hat
matriptas
proteas
treat
f
exogen
proteas
matriptas
find
first
identifi
proteas
besid
trypsin
abl
cleav
hmpv
f
addit
hmpv
appear
util
mani
serin
proteas
influenza
use
ha
process
therefor
offer
strong
potenti
antivir
target
demonstr
greater
advantag
inhibitor
host
proteas
eg
aprotinin
shown
effect
antivir
also
seem
specif
subset
proteas
zhirnov
et
al
argu
specif
proteas
inhibitor
inhibit
one
proteas
might
h
cell
briefli
treat
cell
fusion
buffer
wash
supplement
growth
medium
return
incub
h
allow
fusion
ha
protein
detect
use
haspecif
primari
antibodi
secondari
fluorogen
antibodi
nuclei
stain
use
dapi
magnif
c
vero
cell
express
ha
cleav
matur
process
cell
ad
nm
nm
time
transfect
magnif
advantag
may
result
less
side
effect
respect
influenza
infect
could
repres
specif
target
shown
major
activ
proteas
mice
human
airway
cell
hatesu
et
al
baron
et
al
limburg
et
al
sakai
et
al
tarnow
et
al
howev
evid
applic
broadspectrum
proteas
inhibitor
result
sever
side
effect
specif
one
side
effect
may
consequ
proteas
inhibit
fig
reduc
iav
growth
cell
cultur
mdck
cell
transfect
plasmid
encod
human
matriptas
human
allow
express
protein
h
cell
express
human
matriptas
b
human
c
infect
moi
differ
concentr
ad
well
nontransfect
cell
trypsin
ad
serv
control
mdck
cell
infect
moi
trypsin
ad
assist
viral
propag
differ
concentr
ad
indic
h
infect
supernat
collect
use
immunoplaqu
assay
determin
viral
load
experi
repeat
three
time
dot
repres
viral
titer
singl
experi
statist
analysi
perform
use
nonpair
student
ttest
compar
control
h
respect
sampl
error
bar
indic
standard
deviat
indic
p
extend
horizont
line
within
error
bar
repres
mean
valu
three
independ
replic
tabl
show
mr
strau
et
al
virolog
compound
may
act
differ
target
bodi
report
demonstr
crucial
viru
propag
mice
cell
cultur
suggest
also
play
major
role
human
respiratori
tract
far
howev
unclear
whether
obtain
result
translat
human
studi
shown
exampl
human
matriptas
abl
process
hamilton
whittak
whittak
strau
peptid
assay
suggest
wide
varieti
host
proteas
specif
except
plasmin
test
proteas
combin
peptid
mimick
cleavag
site
differ
ha
subtyp
express
ic
valu
nanomolar
rang
interestingli
valu
obtain
cleavag
inhibit
hmpv
f
substanti
lower
picomolar
rang
suggest
hmpv
cleavag
may
select
inhibit
howev
western
blot
data
show
addit
lowest
concentr
nm
result
cleavag
inhibit
hmpv
f
test
proteas
differ
sensit
influenza
ha
hmpv
requir
investig
pose
sever
potenti
advantag
inhibitor
target
host
proteas
cell
cultur
studi
show
exampl
matriptasemedi
ha
cleavag
effici
inhibit
concentr
nm
contrast
substrat
rang
aprotinin
serin
proteas
inhibitor
shown
reduc
influenza
infect
target
host
proteas
seem
limit
zhirnov
et
al
synthet
peptidelik
molecul
design
inhibit
specif
serin
proteas
hat
test
proteas
potenti
inhibit
proteas
relev
influenza
activ
remain
unclear
sielaff
et
al
meyer
et
al
yamaya
et
al
current
promis
antivir
protein
inhibitor
camostat
alreadi
approv
japan
treatment
chronic
pancreat
sai
et
al
recent
demonstr
camostat
inhibit
influenza
replic
cell
cultur
prevent
viral
spread
pathogenesi
sarscov
mice
inhibit
serin
proteas
yamaya
et
al
zhou
et
al
howev
camostat
appli
prior
viru
infect
administ
mice
via
oral
gavag
zhou
et
al
previou
studi
show
significantli
attenu
influenza
infect
mice
use
concentr
lower
describ
camostat
concentr
intranas
administr
suffici
hamilton
et
al
current
studi
suggest
abl
significantli
inhibit
viral
spread
ongo
infect
need
appli
prior
start
infect
mous
studi
also
show
appli
directli
respiratori
tract
camostat
current
distribut
pill
therefor
less
organ
specif
addit
camostat
synthet
wherea
natur
occur
molecul
may
attenu
potenti
advers
effect
due
nonn
compound
activ
immun
system
futur
research
conduct
test
appli
effici
via
inhal
explor
potenti
side
effect
mice
studi
howev
test
potenti
inhibit
viral
replic
cell
cultur
model
abl
achiev
growth
reduct
approxim
log
h
concentr
nm
one
potenti
explan
nm
unabl
satur
proteas
present
individu
experi
suffici
prevent
viral
growth
addit
continu
overexpress
matriptas
may
produc
artifici
high
quantiti
protein
exceed
inhibitori
capac
problem
could
solv
either
use
higher
concentr
optim
inhibitori
properti
howev
data
also
demonstr
abil
inhibit
proteas
express
cell
surfac
inhibit
limit
proteas
ad
exogen
preincub
inhibitor
fig
express
cytotox
effect
concentr
mm
significantli
therapeut
dosag
requir
inhibit
comparison
studi
concentr
use
nanomolar
rang
publish
inhibitor
requir
micromolar
concentr
sielaff
et
al
meyer
et
al
yamaya
et
al
howev
believ
futur
research
allow
fulli
util
potenti
broadspectrum
antivir
therapi
wu
et
al
recent
describ
kunitz
domain
respons
inhibit
matriptas
wu
et
al
futur
studi
explor
whether
inhibitori
capabl
condens
small
peptid
may
improv
efficaci
abil
inhibit
broad
rang
serin
proteas
involv
activ
influenza
suggest
base
antivir
therapi
could
effici
pathogen
exampl
play
major
role
pathogenesi
also
requir
activ
sarscov
merscov
hmpv
matsuyama
et
al
gierer
et
al
current
treatment
option
virus
limit
therefor
could
becom
viabl
option
potenti
fig
mitig
spread
hmpv
cell
cultur
vero
cell
infect
moi
rghmpv
tpcktrypsin
ad
nm
respect
spread
monitor
cell
treat
demonstr
signific
spread
wherea
treat
sampl
show
detect
viru
howev
minim
detect
viru
error
bar
indic
standard
deviat
independ
sampl
complet
duplic
data
point
plot
within
graph
statist
analysi
perform
use
student
ttest
p
p
p
p
nd
indic
sampl
limit
detect
mdck
cell
infect
moi
trypsin
ad
nm
ad
time
infect
h
post
infect
supernat
collect
h
post
infect
use
immunoplaqu
assay
determin
viral
titer
statist
analysi
perform
use
nonpair
student
ttest
compar
control
h
respect
sampl
error
bar
indic
standard
deviat
indic
p
extend
horizont
line
within
error
bar
repres
mean
valu
three
independ
replic
antivir
therapeut
fulli
exploit
howev
therapeut
potenti
treat
ili
caus
virus
requir
activ
trypsinlik
serin
proteas
may
limit
provid
treatment
option
infect
caus
influenza
hpai
virus
write
committe
world
health
organ
consult
human
influenza
virus
believ
activ
furin
proprotein
convertas
belong
class
subtilisinlik
proteas
horimoto
et
al
preliminari
data
lab
demonstr
inhibit
furinmedi
cleavag
hpai
cleavag
site
peptid
mimic
well
peptid
carri
describ
furin
cleavag
site
data
shown
addit
furin
act
intracellularli
evid
abl
penetr
cell
membran
thu
inhibit
proteas
locat
intracellular
compart
therefor
seem
unlik
abl
inhibit
furin
cell
culturebas
studi
vivo
experi
conclus
believ
potenti
develop
novel
antivir
therapi
contrast
similar
drug
synthet
endogen
express
protein
product
confer
resist
varieti
pathogen
virus
potenti
deliv
directli
respiratori
tract
aerosol
importantli
demonstr
abil
significantli
attenu
ongo
viral
infect
cell
cultur
research
conduct
explor
time
period
demonstr
highest
efficaci
vero
mdck
cell
american
type
cultur
collect
use
influenza
experi
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
mm
hepe
cellgro
fetal
bovin
serum
vwr
vero
cell
use
hmpv
experi
maintain
dmem
hyclon
supplement
fb
sigma
plasmid
encod
ha
gener
describ
hamilton
whittak
plasmid
encod
hmpv
f
gener
describ
kinder
et
al
plasmid
encod
ha
human
human
matriptas
purchas
sino
biolog
inc
plasmid
encod
ha
gener
donat
david
steinhauer
virus
propag
egg
recombin
proteas
purchas
describ
strau
whittak
express
purifi
describ
minor
modif
hamilton
et
al
brief
e
coli
ril
arctic
express
cell
agil
transform
cell
grown
l
luria
broth
contain
kanamycin
od
cell
chill
ice
protein
express
induc
mm
iptg
cell
grown
night
cell
harvest
protein
purifi
previous
describ
hamilton
et
al
protein
elut
incub
glycerol
ad
elut
protein
final
concentr
protein
aliquot
store
protein
concentr
determin
analyz
differ
dilut
sdspage
gel
along
defin
concentr
bsa
ng
gel
stain
coomassi
scan
chemidoc
imag
system
biorad
band
quantifi
use
imag
lab
softwar
biorad
concentr
dilut
determin
base
bsa
concentr
final
concentr
calcul
base
averag
differ
dilut
peptid
assay
carri
describ
strau
whittak
sequenc
hmpv
f
peptid
mimick
hmpv
f
cleavag
site
use
assay
enprqsrfvl
includ
nand
ctermin
modif
describ
ha
peptid
strau
whittak
v
max
calcul
graph
replic
microsoft
excel
determin
slope
reaction
everi
concentr
nm
nm
nm
nm
nm
nm
nm
nm
nm
nm
v
max
valu
plot
graphpad
prism
softwar
concentr
produc
neg
sigmoid
graph
ic
concentr
v
max
inhibit
half
could
extrapol
peptid
proteas
mixtur
sinc
xaxi
concentr
invers
log
taken
number
calcul
ic
nm
cytotox
assay
perform
cell
count
dojindo
molecular
technolog
accord
manufactur
instruct
brief
approx
cell
seed
per
well
plate
grown
night
ad
indic
concentr
dmem
h
use
control
h
later
solut
ad
well
incub
h
absorb
nm
measur
use
spark
micropl
reader
tecan
per
sampl
treatment
three
technic
replic
use
averag
count
one
biolog
replic
experi
conduct
three
time
vero
cell
transfect
pdna
use
lipofectamin
plu
reagent
invitrogen
optimem
gibco
accord
manufactur
protocol
follow
day
cell
wash
pb
starv
cysteinemethionin
defici
media
min
radiolabel
h
cell
lyse
ripa
lysi
buffer
process
describ
previous
schowalt
et
al
fusion
protein
hmpv
immunoprecipit
use
antihmpv
f
monoclon
antibodi
john
william
u
pitt
sampl
run
sdspage
visual
use
typhoon
imag
system
band
densitometri
conduct
use
imagequ
softwar
ge
experi
perform
previous
describ
minor
modif
hamilton
et
al
treatment
trypsin
recombin
matriptas
conduct
describ
hamilton
whittak
hamilton
et
al
western
blot
analysi
cell
transfect
turbofect
invitrogen
accord
manufactur
instruct
cellcel
fusion
assay
conduct
vero
cell
transfect
lipofectamin
accord
manufactur
instruct
antibodi
detect
ha
ha
ha
ha
obtain
biodefens
emerg
infect
research
resourc
repositori
respect
secondari
antibodi
tag
invitrogen
western
blot
membran
scan
use
chemidoc
imag
system
biorad
quantif
pixel
intens
individu
ha
band
measur
use
imagej
softwar
cleavag
effici
calcul
follow
equat
ha
nm
nm
nm
x
cellcel
fusion
assay
carri
describ
hamilton
whittak
mdck
cell
seed
confluenc
plate
one
plate
transform
plasmid
allow
express
human
matriptas
human
one
plate
transform
empti
vector
h
post
transfect
cell
infect
respect
egggrown
viru
moi
approx
differ
concentr
ad
indic
nm
trypsin
ad
cell
transform
empti
vector
h
post
infect
supernat
collect
centrifug
store
viral
titer
determin
use
immuneplaqu
assay
describ
tse
et
al
vero
cell
plate
plate
follow
day
cell
infect
moi
rghmpv
h
cell
wash
pb
optimem
without
nm
tpcktrypsin
ad
incub
h
trypsin
replenish
new
optimem
everi
h
time
point
media
aspir
optimem
ad
cell
follow
scrape
flash
freez
sampl
titer
confluent
vero
cell
dilut
calcul
viral
titer
graph
show
independ
replic
intern
duplic
plot
individu
point
data
point
shown
due
sampl
loss
minimum
point
per
group
independ
replic
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
